Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pritesh Patel

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Clinical Apheresis|May 28, 2021
Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experienceChukwuemeka Uzoka, Li C Liu, Youngmin Park, et al.
Academic Radiology|May 3, 2022
A Clinically Optimal Protocol for the Imaging of Enteric Tubes: On the Basis of Radiologist Interpreted Diagnostic Utility and Radiation Dose ReductionWesley J Klejch, Emily L Marshall, Kayla F Blunt, et al.
Molecular Medicine (Cambridge, Mass.)|May 19, 2026
Gdf15 expression in thermogenic adipocytes regulates diet-induced weight gain in a sex-dependent mannerJayashree Jena, Ayushi Sood, Joshua Peterson, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 17, 2019
When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma RoundsBrendan A Gilmore, Roger A Rodby, David Cimbaluk, et al.
PDA Journal of Pharmaceutical Science and Technology|October 23, 2014
PARENTERAL DRUG ASSOCIATION POINTS TO CONSIDER: Pharmaceutical Quality Metrics Updated September 2014, Steve Mendivil, Joyce Bloomfield, et al.
American Journal of Hematology|April 21, 2020
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemiaSonia Christian, Saad Arain, Pritesh Patel, et al.
Leukemia & Lymphoma|October 26, 2017
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m<sup>2</sup> and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myelomaPritesh Patel, Annie L Oh, Matthew Koshy, et al.
Haematologica|June 19, 2025
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II studyLucas Maahs, Ana Maria Avila, Matthew Koshy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2014
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I studyPritesh Patel, Bulent Aydogan, Matthew Koshy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 11, 2025
Persistent opioid use is associated with a shorter myeloma survivalKaren Sweiss, Ana Maria Avila Rodriguez, John G Quigley, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Apheresis|May 28, 2021
Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experienceChukwuemeka Uzoka, Li C Liu, Youngmin Park, et al.
Academic Radiology|May 3, 2022
A Clinically Optimal Protocol for the Imaging of Enteric Tubes: On the Basis of Radiologist Interpreted Diagnostic Utility and Radiation Dose ReductionWesley J Klejch, Emily L Marshall, Kayla F Blunt, et al.
Molecular Medicine (Cambridge, Mass.)|May 19, 2026
Gdf15 expression in thermogenic adipocytes regulates diet-induced weight gain in a sex-dependent mannerJayashree Jena, Ayushi Sood, Joshua Peterson, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 17, 2019
When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma RoundsBrendan A Gilmore, Roger A Rodby, David Cimbaluk, et al.
PDA Journal of Pharmaceutical Science and Technology|October 23, 2014
PARENTERAL DRUG ASSOCIATION POINTS TO CONSIDER: Pharmaceutical Quality Metrics Updated September 2014, Steve Mendivil, Joyce Bloomfield, et al.
American Journal of Hematology|April 21, 2020
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemiaSonia Christian, Saad Arain, Pritesh Patel, et al.
Leukemia & Lymphoma|October 26, 2017
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m<sup>2</sup> and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myelomaPritesh Patel, Annie L Oh, Matthew Koshy, et al.
Haematologica|June 19, 2025
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II studyLucas Maahs, Ana Maria Avila, Matthew Koshy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2014
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I studyPritesh Patel, Bulent Aydogan, Matthew Koshy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 11, 2025
Persistent opioid use is associated with a shorter myeloma survivalKaren Sweiss, Ana Maria Avila Rodriguez, John G Quigley, et al.
Pageof 7